Balchem Corp

  • Earnings Score
  • Moat Score
  • Safety Score
  • Final Score
  • Market Cap $5.66B
  • PE 47
  • Debt $17.93M
  • Cash $73.69M
  • EV $5.60B
  • FCF $162.58M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$121.54M
EBIT$173.80M
ROE10%
ROA11%
FCF$162.58M
Equity$1.18B
Growth Stability100%
PE46.55
PEG5.32
PB4.81
P/FCF34.8
P/S6
Price/Cash0.01
Debt/Equity0.02
Debt/FCF0.11
Net Margins13%
Gross Margins34%
Op. Margins18%
Earnings CAGR8%
Sales Growth YoY4%
Sales Growth QoQ3%
Sales CAGR8%
FCF CAGR8%
Equity CAGR11%
Earnings Stability0.77
Earnings Growth YoY16%
Earnings Growth QoQ6%
Earnings CAGR 5Y9%
Sales CAGR 5Y10%
FCF CAGR 5Y6%
Equity CAGR 5Y9%
Earnings CAGR 3Y4%
Sales CAGR 3Y4%
FCF CAGR 3Y23%
Equity CAGR 3Y11%
Market Cap$5.66B
Revenue$942.38M
Dividend Yield0%
Payout Ratio21%
Assets$1.60B
Total Debt$17.93M
Cash$73.69M
Shares Outstanding32.28M
EV5.6B
Earnings Score89%
Moat Score91%
Safety Score98%
Final Score93%
Working Capital216.55M
Current Ratio2.98
Gross Profit$324.86M
Shares Growth 3y0%
Equity Growth QoQ6%
Equity Growth YoY15%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Balchem Corp develops, manufactures, distributes, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets. The company offers a wide variety of product lines, with some highly customized and others commodity-oriented. The company operates through three segments - Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. Geographically, it generates majority of the revenue from the United States.

SEC Filings

Direct access to Balchem Corp (BCPC) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Balchem Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Balchem Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 8%
Stability 77%
loading chart...

Balchem Corp Discounted Cash Flow

Fully customizable DCF calculator online for Balchem Corp.

= $2.8B
012345678910TV
fcf$163M$176M$190M$205M$221M$239M$258M$279M$301M$325M$351M$3.5B
DCF$160M$157M$154M$151M$148M$146M$143M$141M$138M$136M$1.4B
Value$2.8B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins10%11%10%15%12%12%12%12%11%12%13%
ROA-11%10%10%11%9%10%11%9%10%11%
ROE-13%11%15%11%11%10%11%11%10%10%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF-4.763.092.651.580.110.090.110.30.110.11
Debt over Equity0.850.640.50.350.230.010.010.020.030.020.02
Growth Stability---100%100%100%100%100%100%100%100%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-2%0%8%8%0%9%14%18%-2%10%
Earnings YoY growth-13%-6%61%-13%1%6%14%10%3%9%
Equity YoY growth-18%12%18%12%8%11%6%7%12%9%
FCF YoY growth--13%35%-2%20%-3%21%5%-28%65%6%